ATH

0.00%

0.3¢ alterity therapeutics limited

Let's see the result from EMA first.

First 2 Last

Share
Profile

Follow
sgsundy

516 Posts.

13

18/11/16

13:50

Post #: 20720003
Share

Originally posted by pjemmett ↑

An auditor friend likes to describe his role as akin to those who roam the battlefield after the battle and bayonet the wounded. In this spirit it might now be time to review the appointment, remuneration and contribution of Dr Ira Shoulson.
When appointed to the board on 13/05/2014 Ira was identified as an expert who had been a consultant to and member of several FDA advisory committees and had been involved in eight successful new drug applications to the FDA.
From the timing of this appointment (3 months after the Reach2HD results) It would be a fair assumption that Prana was already aware that the FDA might have an issue with the dog trials that were run in parallel with the HD trial, with this in mind Prana needed an expert in the workings of the FDA and IRA would have appeared to be the ideal person.
Since his appointment the good Dr has received up until 30 June 2016 a total of $A582747 in non-executive director and consultancy fees from Prana shareholders. That would have been money well spent if the results had been positive.
In my opinion it would be fair to assume that Prana have relied heavily on Ira’s advice and experience concerning the PCH and how best to resolve it to the FDA’s satisfaction.
Whatever advice Ira offered and whether it was followed or not is irrelevant as Prana has failed badly in its efforts to navigate the rocky waters of the FDA and get the PCH lifted, it has wasted the 2½ years since the Reach2HD results and we are now in a far worse position than we would have been if we had pursued a trial via the EMA.
It is difficult to see what value Dr Shoulson can continue to bring to Prana’s future efforts and as such I think his tenure as a director and consultant should be terminate in order to save funds and possibly assist in better strategic decisions being formulated. Perhaps we now need a EMA expert!
All of this is just my opinion.
PJ

Expand

Let's see the result from EMA first.

PBT Price at posting: 6.0¢ Sentiment: None Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

NEU

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

Revolutionary inverter technology leads the clean energy charge

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

TKM

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

Emerald & Azure score Digger & Dealer awards

TNC

True North increases silver metal at QLD's Vero deposit by 20%

Bitcoin: Current State of Play & Where to Next | Swyftx

HZR

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

There are more pages in this discussion • 7 more messages in this thread...

First 2 Last

Add ATH (ASX) to my watchlist

(20min delay)
Last 0.3¢		Change 0.000(0.00%)		Mkt cap ! $15.96M

Open	High	Low	Value	Volume
0.4¢	0.4¢	0.3¢	$2.733K	832.4K

Buyers (Bids)

No.	Vol.	Price($)
32	45274833	0.3¢

Sellers (Offers)

Price($)	Vol.	No.
0.4¢	126718541	16

View Market Depth

No.	Vol.	Price($)
30	44856500	0.003
62	92776603	0.002
28	123111099	0.001
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.004	126718541	16
0.005	26858632	28
0.006	15243927	24
0.007	55868969	31
0.008	23800417	27

Last trade - 15.57pm 09/08/2024 (20 minute delay)

ATH (ASX) Chart

Let's see the result from EMA first.

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

Revolutionary inverter technology leads the clean energy charge

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

Emerald & Azure score Digger & Dealer awards

True North increases silver metal at QLD's Vero deposit by 20%

Bitcoin: Current State of Play & Where to Next | Swyftx

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Let's see the result from EMA first.

Top Stories

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

Revolutionary inverter technology leads the clean energy charge

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

Emerald & Azure score Digger & Dealer awards

True North increases silver metal at QLD's Vero deposit by 20%

Bitcoin: Current State of Play & Where to Next | Swyftx

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News